Synonyms: BMS 387032 | BMS387032 | compound 21 [PMID: 15027863] | SNS 032 | SNS-032 | SNS032
Compound class:
Synthetic organic
Comment: BMS-387032 was originally reported as a potent and selective inhibitor of cyclin-dependent kinase 2 [3]. It has subsequently been discovered to potently inhibit CDK7 and CDK9 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
BMS-387032 (SNS-032) has completed Phase 1 evaluation in clinical trials in patients with advanced liquid and solid cancers, but development has not been advanced further. Click here to link to ClinicalTrials.gov's full list of SNS-032 studies. |